➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKinsey
Express Scripts
Moodys
Mallinckrodt

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ELIQUIS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ELIQUIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01675076 Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Recruiting Boehringer Ingelheim Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Recruiting Heart and Stroke Foundation of Canada Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Recruiting Ottawa Heart Institute Research Corporation Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01884337 Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Recruiting Pfizer Phase 4 2015-03-01 The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement
NCT01884337 Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Recruiting Bristol-Myers Squibb Phase 4 2015-03-01 The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement
NCT01884350 Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) Completed Bristol-Myers Squibb Phase 4 2013-10-01 The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
NCT01885585 Eliquis Regulatory Post Marketing Surveillance (rPMS) Completed Bristol-Myers Squibb N/A 2014-07-01 The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ELIQUIS

Condition Name

Condition Name for ELIQUIS
Intervention Trials
Venous Thromboembolism 14
Atrial Fibrillation 13
Deep Vein Thrombosis 5
Pulmonary Embolism 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ELIQUIS
Intervention Trials
Atrial Fibrillation 19
Thromboembolism 15
Venous Thromboembolism 14
Thrombosis 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ELIQUIS

Trials by Country

Trials by Country for ELIQUIS
Location Trials
United States 93
Canada 23
United Kingdom 17
Netherlands 7
Germany 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ELIQUIS
Location Trials
Minnesota 7
North Carolina 6
California 5
Kansas 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ELIQUIS

Clinical Trial Phase

Clinical Trial Phase for ELIQUIS
Clinical Trial Phase Trials
Phase 4 18
Phase 3 13
Phase 2/Phase 3 3
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ELIQUIS
Clinical Trial Phase Trials
Recruiting 32
Not yet recruiting 20
Completed 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ELIQUIS

Sponsor Name

Sponsor Name for ELIQUIS
Sponsor Trials
Bristol-Myers Squibb 25
Pfizer 8
Ottawa Hospital Research Institute 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ELIQUIS
Sponsor Trials
Other 103
Industry 37
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Johnson and Johnson
Merck
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.